Reuters logo
BRIEF-Trevena reports presentation of positive results from two phase 3 pivotal efficacy studies of olinvo
April 6, 2017 / 11:35 AM / 6 months ago

BRIEF-Trevena reports presentation of positive results from two phase 3 pivotal efficacy studies of olinvo

April 6 (Reuters) - Trevena Inc:

* Trevena-Announced presentation of positive results from two phase 3 pivotal efficacy studies of olinvo

* Trevena Inc - data showed significant efficacy of olinvo in managing moderate-to-severe acute pain

* Trevena - data included head-to-head comparisons to iv morphine suggesting olinvo could be new analgesic option for patients at risk of opioid-related aes

* Trevena - “results suggest that olinvo can be dosed to manage moderate-to-severe acute pain, so that patients may titrate opioid dosing as needed”

* Trevena Inc - results from studies recapitulate earlier clinical trial results

* Trevena Inc - on track to submitting new drug application to FDA for olinvo in Q4 of this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below